BRAF Inhibitors Induce Feedback Activation of RAS Pathway in Thyroid Cancer Cells.

ABSTRACT: BRAF^V600E is the most frequent oncogenic mutation identified in papillary thyroid cancer (PTC). In PTC patients who do not respond to standard treatment, BRAF inhibitors are currently tested as alternative strategies. However, as observed for other targeted therapies, patients eventually develop drug resistance. The mechanisms of BRAF inhibitors response are still poorly understood in a thyroid cancer (TC) context. In this study, we investigated in BRAF^V600E mutated TC cell lines the effects of Vemurafenib and Dabrafenib, two BRAF inhibitors currently used in a clinical setting. We assessed cell proliferation, and the expression and activity of the thyroid function related transporter NIS following the treatment with BRAF inhibitors. In addition, we inve

SUBMITTER: Bonaldi E 

PROVIDER: S-EPMC8198461 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature